In the enHANced treatment with NeoAdjuvant Herceptin (HannaH) study, conducted in patients with early HER2-positive breast cancer, the SC formulation demonstrated pharmacokinetics, efficacy, and a safety profile comparable to IV, with an administration time of <5 min [2]. The gene discussed is ERBB2; the disease is breast carcinoma.